Poseida Therapeutics highlights interim Phase 1 results for P-BCMA-ALLO1

Written by Emily J. Thompson, Senior Investment Analyst

PSTX%

Updated: Dec 09 2024

0mins

P-BCMA-ALLO1 Clinical Data: Poseida Therapeutics will present interim Phase 1 trial data for P-BCMA-ALLO1, showing a 91% overall response rate in patients with relapsed/refractory multiple myeloma, along with promising safety results and no dose-limiting toxicities.
P-CD19CD20-ALLO1 Preclinical Findings: New preclinical data for P-CD19CD20-ALLO1 demonstrate its superior antitumor activity compared to single-target CAR-T therapies, with higher cytotoxicity and sustained immune response, while initial clinical data is expected in 2025.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Poseida Therapeutics highlights interim Phase 1 results for P-BCMA-ALLO1

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trump Administration Requires Tech Firms to Fund $15B Power Generation Plan

IonQ Advances in Quantum Computing with Over $68 Million Revenue in 2025

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch